ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP FOR DENMARK PHARMACEUTICALS

Published Jan 5, 2016
Princeton, NJ—January 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. ISPOR Global Health Care Systems Road Maps can benefit a variety of stakeholders—such as health care decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for health care technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific health care experts and are updated over time to reflect changes in the country’s health care delivery system. Denmark flag map According to the newly published ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals, all Danish citizens are covered by national health insurance. The Danish Medicines Agency decides the reimbursement status for pharmaceutical products and is responsible for legislation concerning pharmaceuticals, medical devices, and clinical trials. Marketing authorization in Denmark is regulated according to European Union (EU) regulation by the European Medicines Agency and does not differ in Denmark from that of other European countries. The total public health care expenditure in Denmark for 2014 were 102,569 billion Danish Krone (DKK) and pharmaceutical spending constituted 12.4% of regional health care expenses. The ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals may be found here. Other ISPOR Global Health Care Systems Road Maps published in 2015 include: -          USA – Pharmaceuticals -          Australia – Pharmaceuticals -          Australia – Medical Devices and Diagnostics   Additional information on all of the ISPOR Tools for Health Care Decision Makers may be found here.

###

 

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×